Purpurogallin 是从栎属植物中提取的天然酚，具有强的黄嘌呤氧化酶 (Xanthine Oxidase) 抑制活性，其IC50为 0.2 μM。Purpurogallin 具有抗氧化和抗炎作用。
| 生物活性 | Purpurogallin is a naturally phenol extracted from theplantsofQuercusspp, has potentxanthine oxidase(XO)inhibitory activity with anIC50of 0.2 μM. Purpurogallin has antioxidant and anti-inflammatory effects[1][2][3]. |
| IC50& Target | IC50: 0.2 μM (xanthine oxidase)[3] |
体外研究
(In Vitro) | Purpurogallin (50 or 100 μM; 7 or 25 hours; BV2 murine microglial cells) treatment attenuates the production of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) by suppressing their mRNA and protein expression in LPS-stimulated BV2 microglial cells[1].
Purpurogallin (100 μM; 75-120 minutes; BV2 murine microglial cells) exhibits anti-inflammatory properties by suppressing the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways in LPS-stimulated BV2 microglial cells[1].
RT-PCR[1] | Cell Line: | BV2 murine microglial cells | | Concentration: | 50 or 100 μM | | Incubation Time: | 7 or 25 hours | | Result: | Attenuated the production of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) by suppressing their mRNA and protein expression. |
Western Blot Analysis[1] | Cell Line: | BV2 murine microglial cells | | Concentration: | 100 μM | | Incubation Time: | 75 minutes, 90 minutes, 120 minutes | | Result: | Suppressed the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways. |
|
体内研究
(In Vivo) | Purpurogallin (100-400 μg/kg; intraperitoneal injection; for 48 or 72 hours; male Sprague-Dawley rats) exerts its neuroinflammation effect through the dual effect of inhibiting IL-6 and TNF-α mRNA expression and reducing HMGB1 protein and mRNA expression[2].
| Animal Model: | Fifty-four male Sprague-Dawley rats (250-350 g) with subarachnoid hemorrhage (SAH)[2] | | Dosage: | 100 μg/kg, 200 μg/kg, 400 μg/kg | | Administration: | Intraperitoneal injection; for 48 or 72 hours | | Result: | Dose-dependently reduced HMGB1 protein expression. High dose reduced TNF-α and HMGB1 mRNA levels. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 100 mg/mL(454.17 mM;Need ultrasonic) 配制储备液 | 1 mM | 4.5417 mL | 22.7087 mL | 45.4174 mL | | 5 mM | 0.9083 mL | 4.5417 mL | 9.0835 mL | | 10 mM | 0.4542 mL | 2.2709 mL | 4.5417 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (9.45 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (9.45 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (9.45 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (9.45 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com